Searching for a Viable Business Model

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

The €4 million (US$4.3 million) project is current good manufacturing practice compliant, and includes an accompanying cartoning machine.

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

The company first announced its intention to build the state-of-the-art facility as part of a €900 million investment in July 2024.

The company now performs product-sterility testing through rapid microbiological methods at two laboratory sites in the United States and one in Germany.